About Chengyuan Technology
Chengyuan Technology was founded in 2022 in Beijing, China, within the biotechnology sector. An AI-based platform is employed to advance synthetic peptide drugs. Syn-mask, a synthetic peptide-based carrier derived from the membrane-penetrating BCP platform, is developed to transport various drug molecules, such as peptides, RNA, and proteins, into cells with noted membrane-penetrating efficiency. Operations focus on drug delivery innovations.
- Headquarter Beijing, China
- Founders Zhang Xiao
-
Sectors
Technology
-
Phone
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Lenovo Capital and Incubator Group
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Chengyuan Technology
Investors in Chengyuan Technology
Chengyuan Technology has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Lenovo Capital and Incubator Group and Gree.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm backed by Lenovo
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Chengyuan Technology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chengyuan Technology
Investment portfolio details for Chengyuan Technology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Chengyuan Technology
Detailed financials for Chengyuan Technology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Chengyuan Technology Comparisons
Peer comparison for Chengyuan Technology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Chengyuan Technology
Detailed competitors of Chengyuan Technology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Chengyuan Technology
Complete news archive for Chengyuan Technology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chengyuan Technology
Chengyuan Technology was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Chengyuan Technology is headquartered in Beijing, China.
Zhang Xiao is the current CEO of Chengyuan Technology. They have also founded this company.
Chengyuan Technology was founded in 2022 in Beijing, China, within the biotechnology sector. An AI-based platform is employed to advance synthetic peptide drugs. Syn-mask, a synthetic peptide-based carrier derived from the membrane-penetrating BCP platform, is developed to transport various drug molecules, such as peptides, RNA, and proteins, into cells with noted membrane-penetrating efficiency. Operations focus on drug delivery innovations.
Chengyuan Technology has 2 investors. Key investors include Lenovo Capital and Incubator Group, and Gree.